Treatment options in hormone-refractory prostate cancer: Current and future approaches

Drugs

Volumn 61, Issue 15, 2001, Pages 2177-2192

  Harris, Katherine A ^a   Reese, David M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN RECEPTOR; ANGIOGENESIS INHIBITOR; ANTIANDROGEN; BICALUTAMIDE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; FLUTAMIDE; GLUCOCORTICOID; HYDROCORTISONE; KETOCONAZOLE; MEGESTROL; MITOXANTRONE; NAVELBINE; NILUTAMIDE; PACLITAXEL; PC SPES; PREDNISONE; PRINOMASTAT; PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; TAXANE DERIVATIVE; TESTOSTERONE; UNINDEXED DRUG; VINBLASTINE; VITAMIN D;

ADVANCED CANCER; ANDROGEN RELEASE; ANDROGEN SYNTHESIS; ANGIOGENESIS; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CASTRATION; CELL CYCLE; CLINICAL RESEARCH; DIARRHEA; DISEASE COURSE; GYNECOMASTIA; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; LUNG EMBOLISM; MALE; METASTASIS; MOLECULAR BIOLOGY; NAUSEA; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION;

ANDROGEN ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; IMMUNOTHERAPY; MALE; MITOXANTRONE; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; TREATMENT OUTCOME; VITAMIN D;

EID: 0035695399     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161150-00003     Document Type: Review

References (134)

1. Cancer statistics 2000
2. Carcinoma of the prostate
3. The question of castration for enlarged prostate
4. The present position of the surgery of the hypertrophied prostate
5. Studies on prostatic cancer: I. The effect of castration, of estrogen, and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
6. Studies on prostatic carcinoma: II. The effect of castration on advanced carcinoma of the prostate gland
7. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
8. Combined androgen blockade for the treatment of metastatic cancer of the prostate
9. Response to orchiectomy following Zoladex therapy for metastatic prostate carcinoma
10. Importance of continued testicular suppression in hormone-refractory prostate cancer
11. Effects of continued androgen-deprived therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: A Southwest Oncology Group report
12. Considerations for the use of testosterone in systemic chemotherapy for prostatic cancer
13. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone
14. Androgen priming and chemotherapy in advanced prostate cancer: Evaluation of determinants of clinical outcome
15. Hormone-refractory (D3) prostate cancer: Refining the concept
16. Purification of a human prostate specific antigen
17. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters
18. Clinical use of prostate specific antigen in patients with prostate cancer
19. Prostate-specific antigen: An important marker for prostate cancer treated by external beam radiation therapy
20. Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized disease
21. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and lukemia Group B study 9181
22. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
23. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
24. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: Association with progression-free survival, pain endpoints and survival
25. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
26. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
27. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points
28. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
29. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
30. Vitamin D in the prevention and treatment of prostate cancer
31. 3 and 9-cis retinoic acid in LNCaP human prostate cancer cells
32. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
33. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens
34. Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
35. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy
36. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer
37. The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected patients with advanced prostate cancer
38. Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome
39. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome
40. Complete remission of hormone refractory adenocarcinoma of the prostate in response to withdrawal of diethylstilbesterol
41. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer
42. The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate
43. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer
44. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
45. Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
46. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables
47. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of 'hormone-refractory' prostate cancer: Toxicity and response
48. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
49. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma
50. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: Cancer and Leukemia Group B Study 9181
51. Megestrol acetate in the treatment of hormone refractory prostate cancer
52. High-dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy
53. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease
54. Studies on the human prostatic cancer cell line LNCaP
55. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
56. Ketoconazole: A possible direct cytotoxic effect on prostate carcinoma cells
57. Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer
58. Phase II study of megestrol acetate for metastatic carcinoma of the prostate
59. A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate
60. Management of progressive metastatic prostate cancer
61. A reevaluation of non-hormonal cytotoxic chemotherapy in treatment of prostatic carcinoma
62. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?
63. Phase II study of mitoxantrone for hormone-refractory metastatic prostate cancer
64. Management of hormone-resistant prostate cancer: An Australian trial
65. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B trial 9182 study
66. Estramustine: A nitrogen mustard/steroid with antimicrotubule properties
67. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: A possible mechanistic basis for its antitumor action
68. Estramustine phosphate sodium: A review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy in prostate cancer
69. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostate cancer
70. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer
71. Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer
72. Estramustine and vinblastine for patients with progressive androgen-independent adenocarcinoma of the prostate
73. Oral estramustine and oral etoposide for hormone-refractory prostate cancer
74. A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer
75. Phase II oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate: Instituto Oncologico Romagnolo, Gruppo Onco-Urologico
76. A phase I/II study of navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer (HRPC)
77. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients
78. Platinum-based chemotherapy for patients (pts) with poorly differentiated hormone refractory prostate cancers (HRPC): Response and pathologic correlations
79. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer
80. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial
81. Randomized phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with hormone escaped progressive metastatic prostate cancer
82. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
83. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostatic carcinoma
84. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
85. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of Cancer and Leukemia Group B Trial 9780
86. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer
87. Phase II study of estramustine (E) combined with docetaxel (D) in patients with androgen-independent prostate cancer (AIPCA)
88. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: Correlation of antitumor effect to phosphorylation of Bcl-2
89. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer preliminary results
90. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer
91. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer
92. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: Scientific basis and design of Southwest Oncology Group Study 9916
93. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate
94. Phase II trial of doxorubicin in bidimensionally measurable prostatic adenocarcinoma
95. Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer
96. Chemotherapy for hormonally refractory advanced prostate carcinoma: A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil
97. Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: A Southwest Oncology Group study
98. Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer
99. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer
100. Oral cyclophosphamide for the management of hormone refractory prostate cancer
101. Oral cyclophosphamide (CTX) for hormone refractory prostate cancer (HRPC)
102. Daily oral cyclophosphamide is effective in hormone-refractory prostate cancer: A PH-I/II pilot study
103. Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients
104. Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer
105. Response of prostate cancer to anti-HER-2/neu antibody in androgen-dependent and -independent human xenograft models
106. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by HER-2/neu tyrosine kinase
107. HER2 expression in androgen-independent prostate cancer
108. Angiogenesis and prostate cancer: In vivo and in vitro expression of angiogenesis factors by prostate cancer cells
109. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
110. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis
111. Efficacy and concentration-response of murine anti-VEGF monoclonal antibody in tumor-bearing mice and extrapolation to humans
112. A phase II trial of humanized monoclonal anti-vascular endothelial growth factor antibody (rhuMAb VEGF) in hormone refractory prostate cancer (HRPC)
113. Changing views of the role of matrix metalloproteinases in metastasis
114. Expression of metalloproteinase genes in human prostate cancer
115. Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: Reduced tissue inhibitor of metalloproteinase secretion by malignant tissues
116. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer
117. A phase I study of AG334, a matrix metalloprotease inhibitor, in patients having advanced cancer
118. Immunocytochemical detection of 1,25-dihydroxyvitamin D3 receptors in normal human tissues
119. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1alpha,25-dihydroxyvitamin D3
120. Vitamin D and prostate cancer: 1,25-dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines
121. Is vitamin D deficiency a risk factor for prostate cancer?
122. Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer
123. 2) administered daily
124. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease
125. Unconventional medicine in the United States: Prevalence, costs, and patterns of use
126. Cancer patients use of non-proven therapy: A 5-year follow-up study
127. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer
128. Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES
129. Induction of apoptosis and down-regulation of bcl-6 in mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES
130. PC-SPES: A unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo
131. Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: A preliminary investigation on human cell lines and patients
132. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer
133. A prospective trial of the herbal supplement PC-SPES, in patients with progressive prostate cancer
134. PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer